CLINICAL TRIAL

An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD

This study will examine the safety and preliminary efficacy of psilocybin mushrooms to treat adults with PTSD. Up to 24 participants will take part in this study. Each participant will ingest psilocybin from dried mushrooms in a chocolate formulation.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2026-03-08
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Suzanne "Sue" Sisley MD

Watch author

Topics and keywords

psilocybin PTSD Pharmacology Clinical Trial Safety Clinical Trial PTSD Psychedelic RECRUITING

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-06-29 Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and EfficacyClinicalTrials.gov · 2026-06-21 Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-03-10 The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-03-05 A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-06-30 Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-22 Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-06-21 Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-21